Celltrion Launches Vegzelma (biosimilar, bevacizumab) for Multiple Cancers in the US
Shots:
- Celltrion reported commercial availability of Vegzelma, a biosimilar referencing Avastin for the treatment of multiple cancers incl. metastatic colorectal & breast cancer
- The company will be responsible for US marketing as part of its plans to strengthen its presence in the world's biggest pharmaceutical market. Vegzelma is the first Celltrion biosimilar to launch in the US
- Vegzelma was approved in the US in Sept 2022 as monotx. or in combination with other agents for multiple cancers & was also approved and/or launched in multiple other countries incl. Canada, Japan & the EU. The company also plans to release its new products & biosimilars, incl. Yuflyma and Remsima SC in the US in the coming future
Ref: The center for Biosimilars | Image: Celltrion
Related News:- Celltrion Healthcare’s Vegzelma (biosimilar, bevacizumab) Receives the Health Canada’s Approval for the Treatment of Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
